ANDA 208077, held by Amneal Pharms. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 208077 (Diclofenac Sodium), held by Amneal Pharms, was first approved by FDA on Mar 18, 2016, with 1 approved supplement and 0 published complete response letters.
Uses for the temporary relief of arthritis pain ONLY in the following areas: hand, wrist, elbow (upper body areas) foot, ankle, knee (lower body areas) this product may take up to 7 days to work for arthritis pain; it is not for immediate relief. If no pain relief in 7 days, stop use
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 18, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium1% · gel;topical | Diclofenac Sodium | OTC |
| Aug 13, 2020 | Supplement 11Labeling · Standard review | Approved | None posted |
| Mar 18, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters